Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | COMT | P21964 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15307431 | 0.88 | GRM5 (0.58) | GRM5SMN1; SMN2TP53MAPTHTR1A | |
| SCHEMBL3833571 | 0.85 | GRM5 (0.60) | GRM5TP53MAPTALDH1A1GAA | |
| SCHEMBL1346311 | 0.84 | GRM5 (0.70) | GRM5SMN1; SMN2TP53MAPTCOMT | |
| SCHEMBL28782831 | 0.81 | GRM5 (0.81) | GRM5SMN1; SMN2TP53MAPTHTR1A | |
| SCHEMBL29712646 | 0.81 | GRM5 (0.81) | GRM5SMN1; SMN2TP53MAPTHTR1A | |
| SCHEMBL8241571 | 0.79 | TP53 (0.81) | GRM5SMN1; SMN2TP53MAPTHTR1A | |
| SCHEMBL28057136 | 0.79 | ERN1 (0.51) | GRM5SMN1; SMN2TP53MAPTKDM4E | |
| SCHEMBL29712712 | 0.78 | GRM5 (0.81) | GRM5SMN1; SMN2TP53MAPTHTR1A | |
| SCHEMBL28782791 | 0.78 | GRM5 (0.81) | GRM5SMN1; SMN2TP53MAPTHTR1A | |
| SCHEMBL3832163 | 0.78 | GRM5 (1.00) | GRM5SMN1; SMN2TP53MAPTHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101730684-B | Sulfonyl-quinoline derivatives | RICHTER GEDEON NYRT | 2013-07-24 | — | — | CN | disclosed |
| EP-2167469-B1 | SULFONYL-QUINOLINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2012-08-15 | — | — | EP | disclosed |
| US-8063220-B2 | Sulfonyl-quinoline derivatives | RICHTER GEDEON NYRT. (HU) | 2011-11-22 | — | — | US | disclosed |
| CN-101730684-A | sulfonyl-quinoline derivatives | RICHTER GEDEON NYRT | 2010-06-09 | — | — | CN | disclosed |
| EP-2167469-A1 | SULFONYL-QUINOLINE DERIVATIVES | Richter Gedeon NYRT (HU) | 2010-03-31 | — | — | EP | disclosed |
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| EP-1962849-B1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT (HU) | 2009-09-30 | — | — | EP | disclosed |
| US-20090042934-A1 | Sulfonyl-Quinoline Derivatives | RICHTER GEDEON NYRT. (HU) | 2009-02-12 | — | — | US | disclosed |
| CN-101346141-A | Quinoline derivatives useful in the treatment of MGLUR5 receptor-mediated disorders | RICHTER GEDEON NYRT (HU) | 2009-01-14 | — | — | CN | disclosed |
| WO-2008155588-A1 | SULFONYL-QUINOLINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2008-12-24 | — | — | WO | disclosed |
| EP-1962849-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | Richter Gedeon NYRT (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072093-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | GRM5, GRIK5, GRM1 | GRM5 1/4885SMN1; SMN2 841/4885TP53 4885/4885 |
| US-20090042934-A1 | Sulfonyl-Quinoline Derivatives | GRM5, GRM1, GRIK5 | GRM5 1/4885SMN1; SMN2 1554/4885TP53 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.